Table 1.
Immunohistochemistry assessment of tissue immunopositivity in protocols I (MM intraperitoneal growth) and IV (early and late treatment of MM by IP injections of mAb C11C1)
| Antibody | Experimental Groups | Cell Type | ||
|---|---|---|---|---|
| PositiveControl | EarlyTreatment | LateTreatment | ||
| Percentage of Immunopositive Cells | ||||
| uPAR | 100.0 ± 0.0 | 100.0 ± 0.0 | 100.0 ± 0.0 | Tumor Cells |
| HK | 77.8 ± 5.3 | 27.2 ± 1.8 | 42.3 ± 7.4 | Endothelial Cells lining blood vessels |
| FGF-2 | 100 ± 0.0 | 100 ± 0.0 | 100 ± 0.0 | Stromal and Tumor Cells |
| VEGF | 5.2 ± 0.9 | 99.2 ± 0.1 | 99.1 ± 0.1 | Stromal and Tumor Cells |
| B2R | 100.0 ± 0.0 | 100.0 ± 0.0 | 100.0 ± 0.0 | Stromal and Tumor Cells |
| B1R | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | Stromal and Tumor Cells |
uPAR urokinase type plaminogen activator receptor. HK high molecular weight kininogen. FGF-2 fibroblast-growth-factor-2. VEGF vascular-endothelial-growth-factor. B2R bradykinin 2 receptor. B1R bradykinin 1 receptor